Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803219 | 0.89 | ALDH1A1 (0.37) | HSPA5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL568468 | 0.83 | — | — | |
| SCHEMBL1039946 | 0.83 | — | — | |
| SCHEMBL24087245 | 0.80 | CTSK (0.37) | HSPA5L3MBTL1ALDH1A1CTSKFBP1 | |
| SCHEMBL7268614 | 0.80 | L3MBTL1 (0.39) | HSPA5L3MBTL1ALDH1A1CTSKFBP1 | |
| SCHEMBL7275150 | 0.80 | L3MBTL1 (0.39) | HSPA5L3MBTL1ALDH1A1CTSKFBP1 | |
| SCHEMBL7268406 | 0.80 | L3MBTL1 (0.39) | HSPA5L3MBTL1ALDH1A1CTSKFBP1 | |
| SCHEMBL1586617 | 0.79 | PLA2G4A (0.36) | HSPA5L3MBTL1CTSKFBP1SLC6A2 | |
| SCHEMBL6061149 | 0.79 | L3MBTL1 (0.35) | HSPA5L3MBTL1CTSKFBP1SLC6A2 | |
| SCHEMBL20098093 | 0.77 | PLA2G4A (0.35) | HSPA5L3MBTL1CTSKFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-115515590-A | Use of masitinib for treating a subpopulation of patients with multiple sclerosis | AB科学有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3273995-B1 | COMBINED USE OF ALGINATE OLIGOMERS AND THE CFTR MODULATOR LUMACAFTOR IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-02-04 | — | — | US | disclosed |
| EP-3768323-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-01-27 | — | — | EP | disclosed |
| CN-111867634-A | Enhanced translocation of micro/nanoparticles across the mucus layer using alginate oligomers | 阿尔吉法玛公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10751363-B2 | Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction | ALGIPHARMA AS (NO) | 2020-08-25 | — | — | US | disclosed |
| EP-1863522-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006101740-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | CA2 3392/4885HSPA5 2480/4885L3MBTL1 1072/4885 |
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | MUC1, ALG1, ST3GAL3 | CA2 1427/4885HSPA5 1579/4885L3MBTL1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.